New pill shows promise for lung cancer patients with Hard-to-Treat mutation

NCT ID NCT02442349

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a daily pill called AZD9291 in 171 people from Asia Pacific with advanced lung cancer that has a specific genetic change (T790M mutation). The goal was to see if the drug could shrink tumors and control the disease after other treatments stopped working. Researchers measured how many patients had their tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD9291 (osimertinib) - a targeted cancer drug taken as a daily tablet
What this could lead to: If successful, this could provide a new treatment option for lung cancer patients with a specific genetic mutation (T790M) whose disease has worsened after other therapies.
What could go wrong: This is a phase 2 trial with a small number of patients (171) and no comparison group, so results may not apply to everyone. The drug may not work for all patients and could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Research Site

Kogarah, 2217, Australia
Research Site

Nedlands, 6009, Australia
Research Site

Woolloongabba, 4102, Australia
Research Site

Beijing, 100021, China
Research Site

Beijing, 100142, China
Research Site

Beijing, 100730, China
Research Site

Changchun, 130000, China
Research Site

Chengdu, 610041, China
Research Site

Chongqing, 400038, China
Research Site

Chongqing, 400042, China
Research Site

Fuzhou, 350014, China
Research Site

Haikou, 570311, China
Research Site

Hangzhou, 310003, China
Research Site

Hangzhou, 310006, China
Research Site

Hangzhou, 310022, China
Research Site

Harbin, 150049, China
Research Site

Jinan, 250117, China
Research Site

Nanjing, 210009, China
Research Site

Shanghai, 200030, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, CN-200433, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430030, China
Research Site

Xi'an, 710032, China
Research Site

Xi'an, 710038, China
Research Site

Zhengzhou, 450008, China
Research Site

Goyang-si, 10408, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 6351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.